Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Arrowhead Pharmaceuticals Corp (ARWR) Misses Q1 EPS by 41c, Revenues Miss
February 7, 2019 4:02 PM ESTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q1 EPS of $0.13, $0.41 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $34.66 million versus the consensus estimate of $71.6 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
... More